Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 (Oral Stable Form) | CJC-1295 (without DAC / Mod GRF 1-29) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. | Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection. |
| Timing | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. | Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection. |
| Cycle Duration | 4-12 weeks. Oral form enables easier long-term use compared to injectable. | 12-24 week cycles with 4-8 week breaks. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
Mod GRF 1-29 (Modified Growth Hormone Releasing Factor, amino acids 1-29) is a truncated and modified GHRH analog that binds to GHRH receptors on anterior pituitary somatotrophs, activating cAMP via Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways. Without the DAC moiety, it has a short half-life of approximately 30 minutes, producing acute GH pulses that more closely mimic natural pulsatile GH secretion. It also stimulates pituitary gene transcription of GH mRNA, preserving endogenous pituitary reserve.
Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.
12-24 week cycles with 4-8 week breaks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →